Geriatrics News

Funding for developing and implementing person-centered care approaches for Alzheimer’s and other dementias is more important to patients with dementia and their caregivers, compared with funding for cure research, according to recently published data.

For older patients with generalized anxiety disorder, telephone-delivered cognitive behavioral therapy and telephone-delivered nondirective supportive therapy achieved similar positive outcomes, though cognitive behavioral therapy resulted in greater symptom reductions.

Medications for mental health are more commonly used among adults aged older than 65 years, despite rarely receiving care from psychiatrists, compared to their younger counterparts, according to recently published data.

Patients with atrial fibrillation who used statins may be less likely to develop nonvascular dementia compared with those who do not use statins.

Results from a randomized, controlled, open-label non-inferiority trial indicate psychotherapy administered via telemedicine had similar results to therapy via same-room treatment for older veterans with major depressive disorder.

Study findings presented at the Alzheimer’s Association International Conference indicate combinations of Alzheimer’s disease biomarkers identified at least 5 years prior to symptom onset can be used to determine which cognitively healthy individuals will progress to mild cognitive impairment due to Alzheimer’s disease.

Among older adults who underwent surgery and were exposed to general anesthesia, women had significantly faster rates of deterioration of cognition, functional status and brain volume, compared with men,  according to recently published data presented at the Alzheimer’s Association International Conference.

Women with mild cognitive impairment have significantly faster rates of cognitive decline, compared with men, according to recently published data presented at the Alzheimer’s Association International Conference.

Metabolomics analyses can provide clinical discrimination, biological pathway information and predict associations between biomarkers and cognition among individuals with Alzheimer’s disease, according to data presented at the Alzheimer’s Association International Conference.

Results from a study using a delayed-start method when assessing solanezumab for treatment of Alzheimer’s disease show benefits of an earlier treatment start time.